{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:56Z","timestamp":1793946476312,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105458","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:42:13Z","timestamp":1782492133000},"page":"105458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-EGFR therapy combined with immune checkpoint inhibitors in recurrent\/metastatic head and neck squamous cell carcinoma: Current landscape and future directions"],"prefix":"10.1016","volume":"226","author":[{"given":"Yong","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3150-4382","authenticated-orcid":false,"given":"Renxian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105458_bib1","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3390\/cancers17233817","article-title":"Emerging and investigational systemic therapies in recurrent\/metastatic head and neck cancer after progression on immunotherapy","volume":"17","author":"Abraham","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105458_bib2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1186\/s12885-025-14619-6","article-title":"Opening of a phase Ib\/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma","volume":"25","author":"Anguera","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105458_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1348045","article-title":"Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent \/ metastatic head and neck squamous cell carcinoma","volume":"14","author":"Black","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231193722","article-title":"Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature","volume":"15","author":"Bloomer","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib6","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.3390\/cancers13112573","article-title":"Paradigm change in first-line treatment of recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"13","author":"Borcoman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105458_bib7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1080\/13696998.2022.2095826","article-title":"Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States","volume":"25","author":"Borse","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2026.105458_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231217959","article-title":"Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer","volume":"16","author":"Burcher","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib9","first-page":"OF1","article-title":"Long-term survival and molecular biomarker evaluation of a phase II cetuximab and nivolumab clinical trial in recurrent\/metastatic head and neck cancer","author":"Chaudhary","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/2767-9764.CRC-22-0443","article-title":"EGFR inhibition by cetuximab modulates hypoxia and ifn response genes in head and neck squamous cell carcinoma","volume":"3","author":"Chaudhary","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105458_bib11","article-title":"Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy","volume":"6","author":"Chiu","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105458_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/cancers13051180","article-title":"Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results of phase I\/II study","volume":"13","author":"Chung","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105458_bib13","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106219","article-title":"A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"135","author":"Dennis","year":"2022","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106861","article-title":"A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer","volume":"154","author":"Desilets","year":"2024","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1442673","article-title":"Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib17","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1007\/s12325-025-03144-4","article-title":"Pembrolizumab with carboplatin and paclitaxel versus alternative systemic treatments recommended for the first-line treatment of recurrent\/metastatic head and neck cancer: an indirect treatment comparison","volume":"42","author":"Dzienis","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105458_bib18","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-25-0073","article-title":"INTERLINK-1: A Phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"31","author":"Fayette","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib19","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1158\/1078-0432.CCR-24-0473","article-title":"Eftilagimod alpha (Soluble LAG3 Protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma","volume":"30","author":"Forster","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","article-title":"Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients","volume":"174","author":"Foy","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105458_bib21","article-title":"Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess","volume":"16","author":"Gao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib23","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-25-0100","article-title":"Phase I clinical trial of the bifunctional EGFR\/TGF-\u03b2 fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors","volume":"31","author":"Hernando-Calvo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111290","article-title":"Unveiling the regulatory mechanism of nimotuzumab on PD-L1 expression in head and neck squamous cell carcinoma patients: Implications for enhanced anticancer treatment strategies","volume":"121","author":"Hu","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.critrevonc.2026.105458_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.114005","article-title":"The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms","volume":"147","author":"Hu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1489451","article-title":"Efficacy and safety of immunotherapy for head and neck squamous cell carcinoma: a meta-analysis of randomized clinical trials","volume":"14","author":"Jiang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1667733","article-title":"Chromosome 11q13 amplification as a decision-making biomarker for anti-PD-1 immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: a prospective cohort study","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.591139","article-title":"Tumor-specific antibody, cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma","volume":"11","author":"Jin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib29","first-page":"524","article-title":"Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy","volume":"33","author":"Kale","year":"2025","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2026.105458_bib30","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1158\/2326-6066.CIR-24-0853","article-title":"PI3K\/Akt signaling pathway regulates CD155 expression involved in resistance to cancer immunotherapy","volume":"13","author":"Kawase","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00262-025-03959-8","article-title":"Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma","volume":"74","author":"Kim","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105458_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2020.00268","article-title":"Current understanding of the mechanisms underlying immune evasion from PD-1\/PD-L1 immune checkpoint blockade in head and neck cancer","volume":"10","author":"Kok","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217702","article-title":"Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory\/ineligible head and neck cancer in palliative setting with survival outcomes","volume":"621","author":"Kothari","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105458_bib34","article-title":"A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody","volume":"9","author":"Koyama","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105458_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102984","article-title":"Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma- a systematic review and meta-analysis","volume":"153","author":"Lau","year":"2020","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1577509","article-title":"Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era","volume":"15","author":"Lee","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib37","article-title":"Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1458479","article-title":"Salvage chemotherapy after progression on immunotherapy in recurrent\/metastatic squamous cell head and neck carcinoma","volume":"14","author":"Llop","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105129","article-title":"Drug-induced interstitial lung disease in recurrent and\/or metastatic head and neck cancer patients treated with cetuximab and\/or nivolumab","volume":"113","author":"Matsuo","year":"2021","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1385094","article-title":"Case report: Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma","volume":"14","author":"Morecroft","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106520","article-title":"Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma","volume":"145","author":"Ngamphaiboon","year":"2023","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13046-023-02691-4","article-title":"Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma","volume":"42","author":"Okuyama","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105458_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00741","article-title":"Correlates of cetuximab efficacy in recurrent and metastatic head and neck squamous cell carcinoma previously treated with immunotherapy","author":"Park","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105024","article-title":"Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes","volume":"111","author":"Park","year":"2020","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105871","article-title":"Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: an updated KEYNOTE-048 based cost-effectiveness analysis","volume":"129","author":"She","year":"2022","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.6004\/jnccn.2024.7085","article-title":"Off-Label\u201d use of checkpoint inhibitors in patients with negative or unknown PD-L1 status in advanced head and neck cancer","volume":"23","author":"Stalker","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2026.105458_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115395","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study","volume":"221","author":"Tahara","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105458_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102938","article-title":"Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1\/PD-L1 immunotherapy","volume":"136","author":"Tahara","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105458_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s11864-023-01080-5","article-title":"Current state and future directions of EGFR-directed therapy in head and neck cancer","volume":"24","author":"Tathineni","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390873","article-title":"Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma","volume":"15","author":"Tsujikawa","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib52","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/13696998.2025.2510807","article-title":"Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia","volume":"28","author":"Urrego-Reyes","year":"2025","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2026.105458_bib53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00262-025-03993-6","article-title":"Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105458_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1273798","article-title":"Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score \u2265 2: a retrospective study","volume":"13","author":"Wu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105458_bib55","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s12325-021-01656-3","article-title":"Cost-effectiveness of pembrolizumab regimens for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Argentina","volume":"38","author":"Wurcel","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2026.105458_bib56","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.3390\/cancers13225716","article-title":"Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists","volume":"13","author":"Xing","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105458_bib57","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3390\/cancers14102351","article-title":"Treatment sequences in patients with recurrent or metastatic head and neck squamous cell carcinoma: cetuximab followed by immunotherapy or vice versa","volume":"14","author":"Yang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105458_bib58","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/s41598-024-57277-7","article-title":"Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent\/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis","volume":"14","author":"Ye","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105458_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104754","article-title":"Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: a cost-effectiveness analysis from Chinese perspective","volume":"107","author":"Zhou","year":"2020","journal-title":"Oral. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:45:42Z","timestamp":1793943942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"alternative-id":["S1040842826003458"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105458","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR therapy combined with immune checkpoint inhibitors in recurrent\/metastatic head and neck squamous cell carcinoma: Current landscape and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105458"}}